CBT-001
Phase 3Small molecule
CBT-001 is one of 15 small molecule programs targeting Pterygium. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in Pterygium
#DrugCompanyPhaseTrials
1Pred Forte
NovartisApproved
Trexall
Alnylam PharmaceuticalsApproved
Mitosol
UUroGen Pharma Ltd.
Approved
Cellcept
RochePhase 3
Avastin
BBio-Thera Solutions
Phase 3
Tripterygium Wilfordii
ZZhi-Hong Liu, M.D.
Approved
Lucentis
RochePhase 2
Yisaipu
SSun Yat-sen University
Approved
Persantine
Boehringer IngelheimPhase 2
PRO-155
LLaboratorios Sophia S.A de C.V.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CBT-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCloudbreak Therapeutics, LLC